FDA Allows De Facto Generic of Pricey Preemie Drug Makena

The Food and Drug Administration has no intention of enforcing a regulation that one drug company sought to exploit to drive out competitors, an FDA official told ABC News. The regulation invoked earlier this month by KV Pharmaceuticals would have allowed to company corner the market for a drug used to prevent preterm births, and sell it for 150 times what had been the going price. KV Pharmaceuticals gained exclusive rights in February to produce a progesterone shot used to prevent preemie...Full Story
Commenting on this article is closed.